Wesley San, MD
Interventional Pain Medicine · Tacoma, WANPI 1376834838
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Medtronic at 48.1% of the total. Reporting peaked in 2022 at $896 and has fallen 60.1% since, to $358 in 2025.
Across 161 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AbbVie$355
- Nevro Corp.$232
- Merz Pharmaceuticals, LLC$222
- Pfizer$166
- Zimvie Inc.$148
- plus $876 from 20 others
What the payments were for
- Food & beverage$3,851100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 78 | $1,851 |
| AbbVie(2 entities) | 17 | $355 |
| Nevro Corp. | 8 | $232 |
| Merz Pharmaceuticals, LLC | 7 | $222 |
| Pfizer | 10 | $166 |
| Zimvie Inc. | 1 | $148 |
| Si-bone, Inc. | 3 | $99 |
| Pacira Therapeutics, Inc. | 4 | $94 |
| Kowa Pharmaceuticals America, Inc. | 5 | $89 |
| Boston Scientific | 3 | $71 |
| ANI Pharmaceuticals, Inc. | 2 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Orexo US, Inc. | 3 | $50 |
| Saluda Medical Americas, Inc. | 2 | $47 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Novartis | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Otto Bock Healthcare LP | 1 | $31 |
| Fidia Pharma USA Inc. | 1 | $30 |
| Catalyst Pharmaceuticals, Inc. | 1 | $30 |
| Virtus Pharmaceuticals LLC | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| GRT US Holding, Inc. | 1 | $19 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$442
- Mobi-C$148
- ADAPTIVESTIM$126
How this compares
$3,851 in reported general payments places this provider in the 60th percentile of 30 interventional pain medicine providers in Washington.
See all interventional pain medicine providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional pain medicine in Tacoma
- Kiang Yien CheungTacoma$12K
- Kashif SaeedTacoma$4K
- German GrinshpunTacoma$2K
- Jaisimha IyengarTacoma$231
- Ray BakerKirkland$1.2M
- Daniel NelsonKirkland$29K
- Kyong KimLakewood$23K
- Hyun HongOlympia$16K
- Glen DavidSeattle$14K
- Diyan RazaSeattle$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.